We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Inappropriate Diagnostic Tests Could Overestimate SARS-CoV-2 Infections Among Vaccinated People

By LabMedica International staff writers
Posted on 23 Nov 2021

The number of SARS-CoV-2 infections among vaccinated people could be overestimated unless appropriate diagnostic tests are used, according to a research team which found that some COVID-19 vaccines induce antibodies that recognize a viral antigen which is not included in the vaccine. More...

A study by the Barcelona Institute for Global Health (ISGlobal; Barcelona, Spain) has revealed that a considerable percentage of people immunized with the Pfizer-BioNTech and Moderna vaccines, which target the SARS-CoV-2 spike protein generate antibodies that can recognize a fragment of another viral protein (the N protein). These rather unexpected findings have implications for the detection of infections in vaccinated people. All vaccines approved in Europe use the SARS-CoV-2 spike protein as antigen, and therefore induce the production of spike-specific antibodies. Because of this, serological tests to establish whether a vaccinated person has been infected measure antibodies to other viral proteins that are not included in the vaccine, such as the N (nucleocapsid) protein.

In their study, the research team closely followed the production and duration of antibodies against different viral antigens in two cohorts of healthcare workers. The unexpectedly found that the mRNA vaccines (Pfizer-BioNTech or Moderna) induce antibodies that not only recognize the spike protein, but can also recognize a fragment of the N protein (the C-terminal region) of SARS-CoV-2. The research team detected, in a considerable percentage of vaccinated individuals, a significant increase of IgG antibodies that can recognize the C-terminal region of the N protein (36% of people who received Moderna and 13% of people who received Pfizer). The Moderna vaccine also induced an increase in antibodies that recognize the full-length N protein, although in a lower percentage of people.

The most probable explanation, according to the researchers, is that spike vaccination can induce antibodies that cross-react with the C-terminal fragment of N. These results are relevant in terms of public health, since it has been proposed to use the N protein to monitor breakthrough infections in vaccinated people. The researchers believe that the N protein (in any case the N-terminal region) should not be used to detect breakthrough infections and that ideally a combination of multiple viral antigens should be used. This would allow a better estimation of vaccine effectiveness.

“With the emergence of new variants that can potentially evade vaccine immunity, it becomes of particular importance to monitor the percentage of vaccinated people that become infected,” explained Carlota Dobaño, first author of the study. “This could lead to an overestimation of breakthrough infections, since a considerable percentage of cases would be misclassified as asymptomatic infections. In consequence, vaccine effectiveness against infections would be underestimated.”

Related Links:
ISGlobal


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.